CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: August 29, 2014
Result type: Reports
Project Number: SR0393-000
Product Line: Reimbursement Review

Generic Name: Pirfenidone

Brand Name: Esbriet

Manufacturer: Hoffmann-La Roche Ltd.

Therapeutic Area: Idiopathic pulmonary fibrosis

Indications: Pulmonary fibrosis (idiopathic, mild to moderate)

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: April 15, 2015

Recommendation Type: List with criteria/condition